成人癌症生存者心力衰竭长期风险的系统综述与荟萃分析
心衰总体相对风险为1.47(95%CI 1.17-1.86),乳腺癌人群为2.57(95%CI 1.35-4.90)。心衰绝对发生率2.1%对对照1.7%,绝对风险差仅0.4%,提示不应对所有生存者普筛。
要点
- 成人癌症生存者心衰风险增加,总体RR 1.47(95%CI 1.17-1.86)。
- 乳腺癌生存者心衰风险更高,RR 2.57(95%CI 1.35-4.90)。
- 绝对风险差仅0.4%,不支持对所有生存者进行普筛。
核心结论
- 成人癌症生存者心衰风险增加,与心脏毒性治疗及标准危险因素相关。
- 生存者与对照的绝对风险差较小,不支持对全部生存者进行普筛。
- 基于年龄、心脏毒性治疗和标准危险因素的风险模型可能有助于选择性筛查。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、MEDLINE和CINAHL数据库。
- 纳入报告成人(≥50岁)癌症生存者(潜在心脏毒性治疗后≥5年)心衰的研究。
- 采用随机效应模型分析心衰关联。
主要发现
- 心衰总体相对风险为1.47(95%CI 1.17-1.86)。
- 心脏毒性治疗与单纯癌症相比,心衰风险相似(RR 1.46,95%CI 0.98-2.16)。
- 心衰总体发生率为2.1%,对照组为1.7%,绝对风险差0.4%。
- 乳腺癌人群(11项研究)心衰总体RR为2.57(95%CI 1.35-4.90)。
- 异质性显著(I2=77.2%),多变量分析校正随访时间(OR 0.99,95%CI 0.97-0.99,p=0.047)、年龄(OR 1.14,95%CI 1.04-1.25,p=0.003)和高血压(OR 0.95,95%CI 0.92-0.98,p<0.001)后残余异质性低(I2=28.7%)。
临床怎么用
- 对成人癌症生存者应关注心衰风险,尤其是乳腺癌生存者。
- 不建议对所有癌症生存者进行心衰普筛。
- 可基于年龄、心脏毒性治疗史和标准危险因素(如高血压)构建风险模型,指导选择性筛查。
局限性
- 异质性显著(I2=77.2%),部分由患者特征差异解释。
- 纳入研究以女性为主(93%),可能限制对其他人群的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer survivors are at increased risk of heart failure (HF). While cardiotoxicity is commonly sought at the time of cancer chemotherapy, HF develops as a result of multiple 'hits' over time, and there is limited evidence regarding the frequency and causes of HF during survivorship. OBJECTIVES: This systematic review sought to investigate the relationship between cardiotoxic cancer therapies and HF during survivorship. METHODS: We searched the EMBASE, MEDLINE and CINAHL databases for studies reporting HF in adult survivors (≥50 years old), who were ≥5 years postpotential cardiotoxic cancer therapy. A random effects model was used to examine the associations of HF. RESULTS: Thirteen papers were included, comprising 190 259 participants (mean age 53.5 years, 93% women). The risk of HF was increased (overall RR 1.47 (95% CI (1.17 to 1.86)). Cardiotoxic treatment, compared with cancer alone, provided a similar risk (RR of 1.46 (95% CI 0.98 to 2.16)). The overall HF incidence rate was 2.1% compared with 1.7% in the control arm-an absolute risk difference of 0.4%. In the breast cancer population ratio (11 studies), the overall HF RR was 2.57 (95% CI 1.35 to 4.90)). Although heterogeneity was significant (I2=77.2), this was explained by differences in patient characteristics; once multivariable analysis accounted for follow-up duration (OR 0.99, 95% CI (0.97 to 0.99), p=0.047), age (OR 1.14, 95% CI (1.04 to 1.25), p=0.003) and hypertension (OR 0.95, 95% CI (0.92 to 0.98), p<0.001), residual heterogeneity was low (I2=28.7). CONCLUSIONS: HF is increased in adult cancer survivors, associated with cardiotoxic cancer therapy and standard risk factors. However, the small absolute risk difference between survivors and controls suggests that universal screening of survivors is unjustifiable. A risk model based on age, cardiotoxic cancer therapy and standard risk factors may facilitate a selective screening process in this at-risk population.
引用
- Wong, Soh, Wang, et al. Long-term risk of heart failure in adult cancer survivors: a systematic review and meta-analysis. Heart. 2024. PMID: 39174318. doi:10.1136/heartjnl-2024-324301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。